Olema Pharmaceuticals, Inc. (OLMA)
6.58
-0.29
(-4.22%)
USD |
NASDAQ |
Oct 16, 16:00
6.58
0.00 (0.00%)
After-Hours: 20:00
Olema Pharmaceuticals Research and Development Expense (Annual) : 157.70M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 157.70M |
| December 31, 2024 | 124.52M |
| December 31, 2023 | 86.14M |
| December 31, 2022 | 82.27M |
| Date | Value |
|---|---|
| December 31, 2021 | 51.10M |
| December 31, 2020 | 13.70M |
| December 31, 2019 | 3.92M |
| December 31, 2018 | 1.693M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| SELLAS Life Sciences Group, Inc. | 16.02M |
| Puma Biotechnology, Inc. | 62.07M |
| ACADIA Pharmaceuticals, Inc. | 328.80M |
| Alnylam Pharmaceuticals, Inc. | 1.320B |
| Anika Therapeutics, Inc. | 25.77M |